163 related articles for article (PubMed ID: 17096152)
1. Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma.
Young MR; Neville BW; Chi AC; Lathers DM; Boyd Gillespie M; Day TA
Cancer Immunol Immunother; 2007 Jul; 56(7):1077-86. PubMed ID: 17096152
[TBL] [Abstract][Full Text] [Related]
2. Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer.
Young MR
J Immunother; 2008; 31(2):148-56. PubMed ID: 18481384
[TBL] [Abstract][Full Text] [Related]
3. Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response.
De Costa AM; Justis DN; Schuyler CA; Young MR
Int Immunopharmacol; 2012 Jul; 13(3):322-30. PubMed ID: 22609090
[TBL] [Abstract][Full Text] [Related]
4. Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.
Johnson SD; Levingston C; Young MR
Anticancer Res; 2016 Jul; 36(7):3261-70. PubMed ID: 27354582
[TBL] [Abstract][Full Text] [Related]
5. Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.
Young MR; Levingston CA; Johnson SD
Int J Cancer; 2016 May; 138(10):2487-98. PubMed ID: 26756968
[TBL] [Abstract][Full Text] [Related]
6. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis.
Rabassa ME; Croce MV; Pereyra A; Segal-Eiras A
BMC Cancer; 2006 Oct; 6():253. PubMed ID: 17064405
[TBL] [Abstract][Full Text] [Related]
7. Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.
Levingston CA; Young MR
Int J Cancer; 2017 Apr; 140(7):1609-1619. PubMed ID: 27914100
[TBL] [Abstract][Full Text] [Related]
8. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma.
Atanackovic D; Blum I; Cao Y; Wenzel S; Bartels K; Faltz C; Hossfeld DK; Hegewisch-Becker S; Bokemeyer C; Leuwer R
Cancer Biol Ther; 2006 Sep; 5(9):1218-25. PubMed ID: 16929165
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood monocyte and T-lymphocyte activation levels at diagnosis predict long-term survival in head and neck squamous cell carcinoma patients.
Aarstad HJ; Vintermyr OK; Ulvestad E; Aarstad HH; Kross KW; Heimdal JH
APMIS; 2015 Apr; 123(4):305-14. PubMed ID: 25801083
[TBL] [Abstract][Full Text] [Related]
10. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses.
Schmitt A; Barth TF; Beyer E; Borchert F; Rojewski M; Chen J; Guillaume P; Gronau S; Greiner J; Möller P; Riechelmann H; Schmitt M
Int J Oncol; 2009 Mar; 34(3):629-39. PubMed ID: 19212667
[TBL] [Abstract][Full Text] [Related]
11. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS
Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Gelbard A; Garnett CT; Abrams SI; Patel V; Gutkind JS; Palena C; Tsang KY; Schlom J; Hodge JW
Clin Cancer Res; 2006 Mar; 12(6):1897-905. PubMed ID: 16551875
[TBL] [Abstract][Full Text] [Related]
14. DNA Methylome Distinguishes Head and Neck Cancer from Potentially Malignant Oral Lesions and Healthy Oral Mucosa.
Milutin Gašperov N; Sabol I; Božinović K; Dediol E; Mravak-Stipetić M; Licastro D; Dal Monego S; Grce M
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961999
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study of MUC1 mucin in premalignant oral lesions and oral squamous cell carcinoma: association with disease progression, mode of invasion, and lymph node metastasis.
Nitta T; Sugihara K; Tsuyama S; Murata F
Cancer; 2000 Jan; 88(2):245-54. PubMed ID: 10640953
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.
De Costa AM; Schuyler CA; Walker DD; Young MR
Cancer Immunol Immunother; 2012 Jun; 61(6):927-39. PubMed ID: 22116344
[TBL] [Abstract][Full Text] [Related]
17. Correlation of serum lactate dehydrogenase and alkaline phosphatase in different histological grades of head and neck squamous cell carcinoma and premalignant lesions.
Bhattacharjee A; Giri S; Roy M; Chakraborty A
J Cancer Res Ther; 2018; 14(5):934-940. PubMed ID: 30197328
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Ca 1 monoclonal antibody in distinguishing oral squamous cell carcinoma from non-malignant or premalignant oral lesions.
Masouredis CM; Green TL; Greenspan JS
J Oral Pathol; 1987 Jul; 16(6):307-9. PubMed ID: 3119804
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma.
Shibuya TY; Wei WZ; Zormeier M; Ensley J; Sakr W; Mathog RH; Meleca RJ; Yoo GH; June CH; Levine BL; Lum LG
Arch Otolaryngol Head Neck Surg; 2000 Apr; 126(4):473-9. PubMed ID: 10772300
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients.
Bose A; Chakraborty T; Chakraborty K; Pal S; Baral R
Cancer Immun; 2008 Jun; 8():10. PubMed ID: 18547033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
